Whedy wang, Ph.D.

Alector

Whedy has over 25 years of experience in the biopharmaceutical industry, including directing biometrics efforts in more than ten NDA and sNDA submissions, three advisory committee meetings and multiple EX-US submissions, all leading to successful approvals. Whedy is currently VP of Biometrics & Digital Science at Alector, a biotech company that is on a mission to slow the progression of neurodegenerative diseases and to one day prevent their occurrence. Prior to joining Alector, she held several senior positions including Vice President of Biometrics and Data Science at Theravance Biopharma, VP of Biometrics at Gilead Sciences Palo Alto (formerly CV Therapeutics), Senior Vice President of Bioinformatics at Orexigen, and Executive Director of Biometrics at Affymax.

At her current as well as previous job postings, Whedy provided strategic input and biometrics oversight to U.S. and EU development and commercial efforts. As a member of the executive team at CV Therapeutics and Orexigen, Whedy contributed to the development of corporate strategy and led life cycle management planning. Additionally, Whedy was the global project leader for Lexiscan® and Ranexa® where her contributions included presenting development rationale and product life cycle management plan to the Board of Directors, and potential EU and Asia partners. Whedy also played a key role in business development discussions that led to successful collaborations such as royalty financing of $185 million for Lexiscan® Injection with TPG-Axon Capital, and license agreement for Ranexa® in 68 countries including EU with the Menarini Group. Whedy holds a M.P.H. in Epidemiology, and a Ph.D. in Biostatistics, both from the University of Michigan, Ann Arbor.

Whedy thrives to be a leader who inspires and empowers others to be their best!! She lives in Palo Alto with her husband and 3 toddler girls. Her favorite daily routine includes reading bedtime stories and playing Animal Crossing with her daughters.